Kornimate/medical-research-clean huggingface dataset:
a study to obtain additional information on the use of cormatrix® cangaroo ecm® envelope

Conditions: Coronary Disease

Summary: actively gather additional information on the use of cormatrix cangaroo ecm envelope in a post market observational study.


Eligibility criteria:
inclusion criteria: 1. subject who has received the cormatrix cangaroo ecm envelope for an implantable electronic device following battery change out or upgrade. 2. signed informed consent exclusion criteria: 1. known sensitivities to porcine material.
effect of sotagliflozin on cardiovascular and renal events in participants with type 2 diabetes and moderate renal impairment who are at cardiovascular risk

Conditions: Heart Failure; Type 2 Diabetes Mellitus; Chronic Kidney Diseases

Summary: the primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (cv) death, hospitalization for heart failure \[hhf\], and urgent visit for heart failure \[hf\] in participants with type 2 diabetes, cardiovascular risk factors, and moderate to severely impaired renal function.


Eligibility criteria:
inclusion criteria : * type 2 diabetes mellitus with glycosylated hemoglobin (hba1c) ≥7%. * estimated glomerular filtration rate (egfr) ≥25 and ≤60 milliliter/minute (ml/min)/1.73 square meter (m\^2). * age 18 years or older with at least one major cardiovascular risk factor or age 55 years or older with at least two minor cardiovascular risk factors. * signed written informed consent. exclusion criteria: * antihyperglycemic treatment has not been stable within 12 weeks prior to screening. * planned coronary procedure or surgery after randomization. * lower extremity complications (such as skin ulcer, infection, osteomyelitis, and gangrene) identified during screening and requiring treatment at randomization. * planning to start a sodium-glucose linked transporter-2 (sglt2) inhibitor during the study. the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
the effect of immediate smoking cessation interventions for smokers with chronic airway diseases

Conditions: Tobacco Cessation; Asthma COPD; Bronchiectasis Adult

Summary: smoking cessation support is provided by smoking cessation outpatient clinics in our country. smokers with chronic airway diseases can also apply to these services by making an appointment from quit lines. quit rates of that group patients were found to be similar to the general population. in novel smoking cessation support approaches immediate cessation support is reported to be more effective than routine practice. the sample in these studies consists of individuals who applied for lung health screening programmes. there is no study in the literature examining the effect of this immediate support on patients with chronic airway diseases' quit success. our aim with this study is to examine impact of immediate cessation support by getting an appointment to the same cessation clinic instantly on our sample's cessation success.

patients who are current smokers (who have smoked at least 100 cigarettes in their lifetime and still smoke daily or some days) will be randomized in a 1:1 ratio to the two arms in sequential order of presentation, after they have been identified and given written informed consent about the study. demographic and clinical features will be filled. a brief smoking cessation intervention will be applied to one group and they will be recommended to apply to smoking cessation outpatient clinics by obtaining appointment from quit lines, as the way of current routine practice. those randomized to the other group will have an immediate appointment at the smoking cessation outpatient clinic in addition to the brief smoking cessation intervention. both patient groups will be called after 1 week by phone to inquire about their smoking cessation status and their application to smoking cessation outpatient clinics. both groups will be called again in the 3rd month and their smoking cessation status, their application to smoking cessation outpatient clinics, and the duration/status of using pharmacological smoking cessation treatments will be questioned.

Eligibility criteria:
inclusion criteria: 1. being age 18 years and over, 2. having diagnoses of asthma and/or copd and/or bronchiectasis for at least 6 months, 3. applying to the chest diseases outpatient clinics, 4. being an current smoker, 5. those who agree to participate in the study, 6. patients who can be reached by phone calls at 1 week and 3 months after randomization. exclusion criteria: 1. those with active psychiatric disorders 2. patients with impaired cognitive functions.

Keywords: tobacco cessation asthma copd bronchiectasis immediate cessation support
a study to compare two different brain imaging techniques in healthy volunteers and in schizophrenic patients

Conditions: Schizophrenia

Summary: a direct comparison of positron emission tomography (pet) (11c-raclopride) and single photon emission computed tomography (spect) (123i-ibzm) d2 ro measurements would allow gsk to gain understanding on the spect results obtained with sb773812, and to accurately interpret future d2 ro results from either pet or spect studies with new compounds.


Eligibility criteria:
inclusion criteria: * not pregnant or becoming pregnant during the study. * no abnormality in clinical examination, clinical laboratory test or ecg. * not taking drugs * patients with schizophrenia, schizophreniform disorder or schizoaffective disorders. * patients with at least 1 month antipsychotic monotherapy with either risperidone, olanzapine or clozapine. * healthy volunteers with no neurological or psychiatric illness. exclusion criteria: * have received other antipsychotic during the last month or neuroleptics during the last year. * if you have taken part in investigations you should not receive a radiation dose of more than 10 msv over any 3 year period. * history of bleeding disorder or are taking medication that affects blood clotting * history of substance dependence (except nicotine) * claustrophobia * gross head deformity. * unable to lie still in the pet or spect camera for 1 hour and a half. * the presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies.

Keywords: bolus 11c-raclopride schizophrenia 123i-ibzm spect receptor occupancy pet mri antipsychotics bolus/infusion
endocervical lidocaine spray for pain control during office hysteroscopy

Conditions: Pain Uterus

Summary: lidocaine spray is used endocervical before office hysteroscopy to reduce the pain

5 sprays of lidocaine is applied 3 minutes before office hysteroscopy

Eligibility criteria:
inclusion criteria: patients indicated for diagnostic hysteroscopy for infertility or aub. postmenstrual between days 7 and 11 of the cycle ( except in irregular bleeding) exclusion criteria: contraindication to office hysteroscopy neurological disorders affecting the evaluation of pain. previous cervical surgery.

Keywords: office hysteroscopy lidocaine spray
rebecca real-world early breast cancer management

Conditions: Breast Cancer

Summary: this is a french observational, national, multicenter prospective cohort study of patients with her2-negative ebc treated with olaparib at their physician's discretion.

the purpose to this observational study is to evaluate the rate of completion of adjuvant olaparib treatment for her2-negative early breast cancer patients in france.

Eligibility criteria:
inclusion criteria: * male or female aged ≥ 18 years * patient diagnosed with her2-negative ebc * patient about to be initiated with adjuvant olaparib at their physician's discretion * patient has been informed and does not object to participation in the study. exclusion criteria: * patient not consenting to participate. * patients included in the early access program
t wave alternans in hemodialysis

Conditions: End Stage Renal Disease; Coronary Heart Disease; Congestive Heart Failure

Summary: the purpose of this study is to determine if the hemodialysis procedure changes the risk for cardiac arrest in patients.

one-third to one-quarter of hemodialysis patients die of sudden cardiac death (scd). the hemodialysis procedure may theoretically increase the risk of scd. this study uses t wave alternans, a noninvasive marker of scd, to objectively determine whether the hemodialysis procedure alters the risk of scd in hemodialysis patients.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * normal sinus rhythm exclusion criteria: * inability to give written informed consent * active cardiac ischemia * pacemaker * inability to perform a brief walking treadmill test

Keywords: hemodialysis sudden cardiac death
evaluation of dental implants after using several bone splitting techniques

Conditions: Jaw, Edentulous

Summary: in both full and partial tooth loss, the usage of dental implants for an artificial replacement for missing teeth is a well-known and reasonable treatment modality that leads to high patient satisfaction and enhanced life quality. (1) in both full and partial tooth loss, the usage of dental implants for an artificial replacement for missing teeth is a well-known and reasonable treatment modality that leads to high patient satisfaction and enhanced life quality because there is insufficient bone volume to support the dimensions of the implants, the horizontal deficiencies of the alveolar ridge obstruct implant-supported rehabilitation, which has an impact on the ultimate prosthetic outcome from both a functional and cosmetic standpoint (2). the split crest technique reduces treatment time, the number of surgical procedures required, and even the risk of complications for the patients, making it more readily accepted by them. it also allows dental implants to be installed in the same surgical procedure and does not require a donor area to remove the graft. (3) in this study, patients underwent rehabilitation of posterior missing teeth in the narrow mandibular ridge by dental implant after ridge splitting by osseodensification, piezosurgery, or magnetic mallet.

the study's objective is to compare ridge width gain after osseodensification, piezosurgery, or magnetic mallet after ridge splitting with simultaneous implant implantation in individuals with narrow alveolar ridges. 36 patients will be randomly allocated into three groups. ridge splitting followed by piezo and bone expander will be performed with simultaneous implant placement in group 1. osseodensification bure will be performed after ridge splitting with simultaneous implant placement in group 2. magnetic mallet will be performed after ridge splitting with simultaneous implant placement in group 3.

Eligibility criteria:
inclusion criteria: 1. patients who can to follow-up appointments. 2. alveolar ridge width of at least 3 mm with sufficient height to place a regular implant. 3. availability of spongy bone with at least 1 mm in width between the cortical plates. 4. free of any underlying conditions that can impact bone metabolism. exclusion criteria: 1. the presence of severe concavity on the vestibular or palatal side of the alveolar ridge. 2. patients with uncontrolled periodontal diseases. 3. patients who have undergone radiotherapy in the head and neck area. 4. smokers or patients with parafunction habits.

Keywords: osseodensification piezosurgery magnetic mallet
pre-emptive transjugular intrahepatic portosystemic shunt (tips) in cystic fibrosis related liver disease

Conditions: Cystic Fibrosis Liver Disease; Portal Hypertension Due to Cystic Fibrosis (Disorder); Portal Hypertension, Noncirrhotic

Summary: portal hypertension (pht) and its sequelae are the most clinically important manifestation in cystic fibrosis related liver disease (cfld), with end-stage liver failure as a late and rare manifestation. the aim is to evaluate the safety and efficacy of a pre-emptive transjugular intrahepatic portosystemic shunt (tips) for the prophylaxis of variceal bleeding in pediatric cfld patients with subclinical non-cirrhotic portal hypertension (ncph)

cystic fibrosis (cf) is the most frequent autosomal recessive disorder in caucasians caused by a mutation in the cystic fibrosis transmembrane conductance regulator gene. cystic fibrosis associated liver disease (cfld) is a well-known complication and includes a wide range of hepatobiliary diseases. the clinical outcome in cfld is largely determined by pht and its sequelae. variceal bleeding is the most feared complication. currently, there is no medical therapy to delay or reverse clinically established cfld.treatment focuses on screening for and managing the complications of portal hypertension and optimizing nutritional status. eventually, liver transplantation (lt) is an effective therapeutic option for cf patients with end-stage liver failure, treatment resistant, and complicated portal hypertension. tips placement is a well-established procedure for portal vein decompression in adults. in retrospective case studies of severe cfld cirrhosis in pediatric populations, tips has been proven a feasible option in acute or refractory variceal bleeding and as a bridge to lt. in cfld patients, little data are available on the long-term outcome of treatments to mitigate pht. in this trial, the primary aim was to evaluate the safety and efficacy of a pre-emptive tips for the prophylaxis of variceal bleeding in non-cirrhotic cfld with early pht. the secondary aim was to investigate the long-term clinical outcome of a pre-emptive tips and in more particular, whether tips might effectively postpone lt.

Eligibility criteria:
inclusion criteria: * cystic fibrosis * liver disease detected by an abnormal physical examination (hepatomegaly or splenomegaly, confirmed on us), abnormalities of liver function tests (increase of ast, alt, ggt levels above the upper normal limits) or ultrasonographic evidence of liver involvement (us liver score ≥ 5). * indirect signs of portal hypertension on doppler us * progressive portal hypertension / liver disease on bi-monthly follow-up, evaluated by physical examination, blood analysis and us exclusion criteria: * cirrhosis on biopsy * symptomatic portal hypertension (portosytemic pressure gradient \> 10 mmhg)

Keywords: transjugular intrahepatic portosystemic shunt gastrointestinal bleeding hypersplenism
bariatric endoscopy and nafld

Conditions: Obesity; NAFLD; Liver Steatosis; Liver Fibrosis

Summary: find out how bariatric endoscopy will influence the clinical course of non-alcoholic fatty liver disease.

the study will test and investigate the impact of bariatric endoscopy (various types of intragastric balloons, endoscopic sleeve gastroplasty, aspiration therapy) on components of the metabolic syndrome in obese patients, especially on influencing non-alcoholic steatosis and steatohepatitis and signs of liver fibrotization and weight reduction. the method consists of performing a mini-invasive endoscopic procedure and, as a result, reduced food intake.

Eligibility criteria:
inclusion criteria: * age between 21-70 years * bmi \>27 kg/m2 * must be able to comply with all study requirements for the duration of the study as outlined in the protocol. this includes complying with the visit schedule as well as study-specific procedures such as clinical assessment, endoscopy, radiography, as well as laboratory investigations * must be able to understand and be willing to provide written informed consent * patient living within radio range 300 km from the study center * failure of the cognitive-behavioral approach to weight reduction exclusion criteria: subjects meeting any of the following exclusionary criteria cannot be enrolled in the study: * bmi \<27 * history of gastric surgery. * previous technical difficulties in gastric and duodenal endoscopy or inability to perform endoscopy * history of git diseases such as achalasia, esophageal motility disorders, severe esophagitis or gastritis, the recent history of ulcers, history of steatosis or obstruction in the git * proven celiac disease * previous irreversible endoscopic procedures and surgical treatment of obesity * chronic and acute pancreatitis * active or chronic infectious hepatitis * known liver disease or suspected pbc, psc, autoimmune hepatitis, alpha1-antitrypsin deficiency, wilson's disease, hereditary hemochromatosis, known cirrhosis or history of hepatic decompensation, ast or alt\> 5-8x uln * type 1 or type 2 diabetes with insulin * history of malignant disease * specific genetic or hormonal disorders associated with obesity (prader-willi syndrome, mc4r mutations, etc.) * serious disorders of blood clotting and hematopoiesis * severe forms of psychiatric illness (endogenous depression, schizophrenia, suicidal tendencies, psychosis) * uncontrolled hypertension (systolic bp\> 150 mm hg or diastolic bp\> 100 mm hg) or severe heart disease (severe cardiac dysfunction, etc.) * serious autoimmune diseases or long-term use treated with glucocorticoids or immunosuppressive therapy * disorders of thyroid function unresponsive to processing. * renal impairment with gfr \ 1000 mg / day * substance use including excessive alcohol use (\> 21 units / week for men and\> 14 units / week for women, - 1 unit (250ml 12 ° or 330ml 10 ° beer; 100ml wine; 25ml = small spirits of spirits)) * pregnancy

Keywords: obesity nafld liver steatosis liver fibrosis bariatric endoscopy weight loss
preventing post-stroke depression

Conditions: Depression; Cerebrovascular Accident

Summary: this study will evaluate the effectiveness of both drug and non-drug treatments in preventing depression after a stroke.

the development of depression after a stroke is a serious condition that can have negative effects on thought, emotions, and overall daily functioning, particularly in the first year following the stroke. evidence suggests that antidepressants may be used to prevent post-stroke depression. this study will treat nondepressed stroke patients with antidepressants or problem solving therapy (pst) to determine the most effective treatments for preventing depression. participants in this study will be randomly assigned to receive pst, escitalopram, or placebo (an inactive pill) for 12 months. participants who display depressive symptoms for 2 weeks or more will be removed from the study. after 12 months, treatment will be discontinued and participants will be monitored for an additional 6 months.

Eligibility criteria:
inclusion criteria: * stroke within the last 120 days exclusion criteria: * dsm (diagnostic and statistical manual) iv criteria for major or minor depressive disorder * heart, respiratory, kidney, or liver failure; severely disabling musculoskeletal disorder; or cancer * diagnosis of neurodegenerative disorders such as parkinson's disease, alzheimer's disease, multiple system atrophy, or huntington's disease * pre-existing dementia or aphasia with severe language comprehension deficits * alcohol or substance abuse or dependence within the last 12 months * recurrent unipolar or bipolar disorder prior to the stroke

Keywords: stroke
hemodynamic effects of bpa at rest and during exercise in cteph

Conditions: Chronic Thromboembolic Pulmonary Hypertension

Summary: chronic thromboembolic pulmonary hypertension (cteph) is characterized by obstruction of the pulmonary vasculature by residual organized thrombi, leading to increased pulmonary vascular resistance (pvr), progressive pulmonary hypertension, and right heart failure. medical therapy and balloon angioplasty (bpa) are effective treatment alternatives in lowering pulmonary pressures and increasing pulmonary flow. the aim of this study is to assess the hemodynamic effects of bpa or medical therapy on the pressure-flow relationship in the pulmonary vasculature and the pulmonary vascular compliance.

chronic thromboembolic pulmonary hypertension \[cteph\] is a rare condition with a significant risk of morbidity and mortality. the primary cause of cteph is thrombotic lesions, which did not resolve after acute pulmonary embolism. this causes increased pulmonary vascular resistance \[pvr\], leading to secondary remodeling of pulmonary arteries causing pulmonary hypertension and ultimately progressive right heart failure. the treatment of choice is surgical pulmonary endarterectomy \[pea\], however up to 40% cases are not treated surgically, due to operability, anatomic location of the lesions, patient choice and comorbidities significantly increasing procedural risk. a new alternative procedure, balloon pulmonary angioplasty \[bpa\] has been proposed for patients with inoperable cteph or persistent pulmonary hypertension after pulmonary endarterectomy (pea) and is currently characterized with good outcome in functional capacity, hemodynamic parameters, biomarkers, and health-related quality of life. exercise stress tests of the pulmonary circulation are used in workup and diagnosis of pulmonary hypertension as a hemodynamic abnormality. the approach has allowed identification of patients with normal or marginally increased mpap at rest but with symptomatic increases in mpap at exercise, related to either increased resistance or increased left atrial pressure. although this differential diagnosis is of obvious therapeutic relevance, guidelines about exercise stress studies of the pulmonary circulation have not been developed until now for lack of robust evidence allowing for a consensus on clearly defined cutoff values. neither the pathophysiology of the exercise limitation nor the underlying mechanisms of the bpa - induced improvement were studied before. therefore the aim of this study is to assess the hemodynamic effects of bpa treatment on the pressure-flow relationship in the pulmonary vasculature and the pulmonary vascular compliance. furthermore, the investigators will explore possible differences in treatment effect across centers. especially explore the timing of medical therapy vs balloon angioplasty. .

Eligibility criteria:
inclusion criteria: -patients with cteph or cted eligible for balloon pulmonary angioplasty. exclusion criteria: -patients unable to perform ergometer exercise
telemedicine consultation in trauma and orthopedic

Conditions: Trauma; Congenital Bone and Joint Abnormalities; Joint Diseases; Orthopedic Surgery Complications

Summary: the purpose of this study is to determine whether telemedicine consultations (lead by standard scheme)allows to increase quality of anatomical and functional outcomes and improve clinical work-flow at patients with acute bone and joint trauma, hip pathology and congenital orthopedics abnormalities.

levels of bad outcomes, untimely death and disability due to acute trauma, specific orthopedic pathology (congenital, coxarthrosis) and non-efficient organisation of clinical work-flow are still very high (especially in rural areas). standard telemedicine work stations (with special protocols and manuals for original approach to telemedicine activity organisation and management) will be placed into small municipal and rural hospitals. telemedicine links will be established between 3rd level trauma\&ortho center and remote sites. synchronous and asynchronous teleconsultations will be perform for help in evidence-based timely clinical decisions, continual support of clinical wor-flow and treatment process.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of injury of locomotorium (isolated or polytrauma) * clinical diagnosis of bone and joint congenital abnormalities or intranatal injury * clinical diagnosis of knee, hip arthrosis * clinical diagnosis of complication of surgery (unstable, fracture of construction etc) * diagnosis is already present * primary decision of clinical strategy have to be done (transportation, level of care, method of treatment, surgery peculiarities) * indications for teleconsultations determined by physician exclusion criteria: * diagnosis is not present * patient's self-request for teleconsultations * no reliable feed-back with attending physician

Keywords: fracture coxarthrosis complication congenital abnormalities bone joint telemedicine transportation decision making outcomes